EP3146047A4 - Antisense antibacterial compounds and methods - Google Patents

Antisense antibacterial compounds and methods Download PDF

Info

Publication number
EP3146047A4
EP3146047A4 EP15795398.5A EP15795398A EP3146047A4 EP 3146047 A4 EP3146047 A4 EP 3146047A4 EP 15795398 A EP15795398 A EP 15795398A EP 3146047 A4 EP3146047 A4 EP 3146047A4
Authority
EP
European Patent Office
Prior art keywords
methods
antibacterial compounds
antisense antibacterial
antisense
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15795398.5A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3146047A1 (en
Inventor
Bruce L. Geller
David Greenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon State University
University of Texas System
Original Assignee
Oregon State University
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon State University, University of Texas System, University of Texas at Austin filed Critical Oregon State University
Priority to EP19167404.3A priority Critical patent/EP3569252B1/en
Publication of EP3146047A1 publication Critical patent/EP3146047A1/en
Publication of EP3146047A4 publication Critical patent/EP3146047A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
EP15795398.5A 2014-05-19 2015-05-15 Antisense antibacterial compounds and methods Withdrawn EP3146047A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP19167404.3A EP3569252B1 (en) 2014-05-19 2015-05-15 Antisense antibacterial compounds and methods

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462000431P 2014-05-19 2014-05-19
US201562129746P 2015-03-06 2015-03-06
PCT/US2015/031213 WO2015179249A1 (en) 2014-05-19 2015-05-15 Antisense antibacterial compounds and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP19167404.3A Division EP3569252B1 (en) 2014-05-19 2015-05-15 Antisense antibacterial compounds and methods

Publications (2)

Publication Number Publication Date
EP3146047A1 EP3146047A1 (en) 2017-03-29
EP3146047A4 true EP3146047A4 (en) 2018-04-04

Family

ID=54554572

Family Applications (2)

Application Number Title Priority Date Filing Date
EP15795398.5A Withdrawn EP3146047A4 (en) 2014-05-19 2015-05-15 Antisense antibacterial compounds and methods
EP19167404.3A Active EP3569252B1 (en) 2014-05-19 2015-05-15 Antisense antibacterial compounds and methods

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP19167404.3A Active EP3569252B1 (en) 2014-05-19 2015-05-15 Antisense antibacterial compounds and methods

Country Status (6)

Country Link
US (1) US10391098B2 (enExample)
EP (2) EP3146047A4 (enExample)
JP (1) JP6687542B2 (enExample)
AU (1) AU2015264449B2 (enExample)
CA (1) CA2948568A1 (enExample)
WO (1) WO2015179249A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0992230A3 (en) 1998-10-08 2001-08-22 KCI Licensing, Inc. Medical pumping apparatus and related methods
AU2015258895A1 (en) 2014-05-16 2016-11-24 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
AU2015264449B2 (en) 2014-05-19 2022-05-05 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
WO2016108930A2 (en) 2014-12-31 2016-07-07 Geller Bruce L Antisense antibacterial compounds and methods
EP3394261A4 (en) * 2015-12-23 2019-11-27 Oregon State University ANTIBACTERIAL ANTISENSE COMPOUNDS AND METHOD
EP3394262B1 (en) 2015-12-23 2024-08-28 Oregon State University Antisense antibacterial compounds and methods
EA201892467A1 (ru) * 2016-04-29 2019-05-31 Сарепта Терапьютикс, Инк. Олигонуклеотидные аналоги, нацеленные на lmna человека
US20200283768A1 (en) * 2017-10-23 2020-09-10 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
GB2579253A (en) 2018-11-28 2020-06-17 Pedanius Therapeutics Ltd Antibacterial antisense agents
CN110885364B (zh) * 2019-12-26 2021-02-02 江南大学 一种促进N-乙酰氨基葡萄糖生产的RamA转录因子突变体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007009094A2 (en) * 2005-07-13 2007-01-18 Avi Biopharma, Inc. Antisense antibacterial method and compound
WO2008008113A1 (en) * 2006-07-13 2008-01-17 Avi Biopharma, Inc. Improved antibacterial antisense oligonucleotide and method

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
EP0215942B1 (en) 1985-03-15 1995-07-12 Antivirals Inc. Polynucleotide assay reagent and method
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
AU659482B2 (en) 1991-06-28 1995-05-18 Massachusetts Institute Of Technology Localized oligonucleotide therapy
PT876165E (pt) 1995-12-18 2006-10-31 Angiotech Biomaterials Corp Composicoes de polimeros reticulados e processos para a sua utilizacao
US6245747B1 (en) 1996-03-12 2001-06-12 The Board Of Regents Of The University Of Nebraska Targeted site specific antisense oligodeoxynucleotide delivery method
US20060241075A1 (en) 2001-05-18 2006-10-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA)
US20040029129A1 (en) 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
WO2004093788A2 (en) 2003-04-17 2004-11-04 The Trustees Of Columbia University In The City Ofnew York Desmoglein 4 is a novel gene involved in hair growth
US7468418B2 (en) 2003-04-29 2008-12-23 Avi Biopharma., Inc. Compositions for enhancing transport of molecules into cells
US20050288246A1 (en) 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
AU2005327188C8 (en) 2004-07-02 2011-09-22 Avi Biopharma, Inc. Antisense antibacterial method and compound
US20080125583A1 (en) 2005-02-11 2008-05-29 International Business Machines Corporation Ribonucleic acid interference molecules
US8067571B2 (en) * 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US8143389B2 (en) 2005-08-25 2012-03-27 Texas Tech University Inhibiton of metallo-β-lactamase by double-stranded DNA
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
ES2694726T3 (es) 2007-06-29 2018-12-26 Sarepta Therapeutics, Inc. Conjugados peptídicos específicos de tejido y métodos
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
HRP20140646T1 (hr) 2007-11-15 2014-09-26 Sarepta Therapeutics, Inc. Postupak sinteze morfolino oligomera
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
US9914745B2 (en) 2009-08-14 2018-03-13 Indian Association For The Cultivation Of Science Morpholino-based antisense agent
WO2012031243A2 (en) 2010-09-03 2012-03-08 Avi Biopharma, Inc. dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
PT2623507T (pt) 2010-09-30 2016-12-23 Nippon Shinyaku Co Ltd Derivado de ácido morfolino-nucleico
EP3067420A1 (en) 2010-11-12 2016-09-14 Sarepta Therapeutics, Inc. Antisense antibacterial compounds and methods
US20120213663A1 (en) 2011-02-23 2012-08-23 King Fahd University Of Petroleum And Minerals Method of removing e. coli bacteria from an aqueous solution
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
KR102183273B1 (ko) 2011-05-05 2020-11-27 사렙타 쎄러퓨틱스, 인코퍼레이티드 펩타이드 올리고뉴클레오타이드 접합체
KR101317263B1 (ko) 2011-07-05 2013-10-10 (주)지노첵 리얼타임 ｐｃｒ을 이용한 카바페넴 내성 장내균 검사 방법 및 키트
WO2013011072A1 (en) 2011-07-20 2013-01-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Carbapenemase and antibacterial treatment
AU2015258895A1 (en) 2014-05-16 2016-11-24 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
AU2015264449B2 (en) 2014-05-19 2022-05-05 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
WO2016108930A2 (en) 2014-12-31 2016-07-07 Geller Bruce L Antisense antibacterial compounds and methods
EP3394261A4 (en) 2015-12-23 2019-11-27 Oregon State University ANTIBACTERIAL ANTISENSE COMPOUNDS AND METHOD
EP3394262B1 (en) 2015-12-23 2024-08-28 Oregon State University Antisense antibacterial compounds and methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007009094A2 (en) * 2005-07-13 2007-01-18 Avi Biopharma, Inc. Antisense antibacterial method and compound
WO2008008113A1 (en) * 2006-07-13 2008-01-17 Avi Biopharma, Inc. Improved antibacterial antisense oligonucleotide and method

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DAVID E. GREENBERG ET AL: "Antisense Phosphorodiamidate Morpholino Oligomers Targeted to an Essential Gene Inhibit Burkholderia cepacia Complex", JOURNAL OF INFECTIOUS DISEASES. JID, vol. 201, no. 12, 15 June 2010 (2010-06-15), CHICAGO, IL., pages 1822 - 1830, XP055425953, ISSN: 0022-1899, DOI: 10.1086/652807 *
GELLER B L ET AL: "Inhibition of gene expression in Escherichia coli by antisense phosphorodiamidate morpholino oligomers", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 47, no. 10, 1 October 2003 (2003-10-01), pages 3233 - 3239, XP002402831, ISSN: 0066-4804, DOI: 10.1128/AAC.47.10.3233-3239.2003 *
See also references of WO2015179249A1 *

Also Published As

Publication number Publication date
JP6687542B2 (ja) 2020-04-22
EP3569252A2 (en) 2019-11-20
EP3569252A3 (en) 2020-03-04
EP3569252B1 (en) 2021-12-15
JP2017522004A (ja) 2017-08-10
CA2948568A1 (en) 2015-11-26
AU2015264449A9 (en) 2022-05-05
WO2015179249A1 (en) 2015-11-26
US20160106857A1 (en) 2016-04-21
EP3146047A1 (en) 2017-03-29
AU2015264449A1 (en) 2016-11-24
AU2015264449B2 (en) 2022-05-05
US10391098B2 (en) 2019-08-27

Similar Documents

Publication Publication Date Title
EP3171299A4 (en) Multi-smartcard
EP3129108A4 (en) Hoverboard
EP3143141A4 (en) Antisense antibacterial compounds and methods
EP3146047A4 (en) Antisense antibacterial compounds and methods
EP3220919A4 (en) Antibacterial compounds
EP3193878A4 (en) Compounds and methods
EP3373875B8 (en) Bandage
EP3240794A4 (en) Antisense antibacterial compounds and methods
EP3239995A4 (en) Solenoid
EP3105244A4 (en) Antibacterial agents
IL250405A0 (en) Antibacterial sideromycins
EP3194628A4 (en) Antisense compounds and uses thereof
EP3166949A4 (en) Thienothiophene-isoindigo
EP3194591A4 (en) Antisense compounds and uses thereof
EP3209667A4 (en) Nargenicin compounds and uses thereof as antibacterial agents
AU2014903020A0 (en) Antibacterial Agent
EP3216346A4 (en) Anti-bacterial agent
HK1237337A1 (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
AU2015901676A0 (en) Compounds and Methods
AU2014904372A0 (en) Treatment
EP3110412A4 (en) 4-benzylsulfonyl-2-butenenitrile
AU2014905285A0 (en) Gyrostabiliser Improvements
AU2014902238A0 (en) Antibacterial compounds
AU2014905171A0 (en) GroundControl
AU2014900308A0 (en) Antibacterial compounds

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20161219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/00 20060101ALI20171123BHEP

Ipc: A61K 47/64 20170101AFI20171123BHEP

Ipc: C12N 15/11 20060101ALI20171123BHEP

Ipc: A61K 38/08 20060101ALI20171123BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1235827

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20180302

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/11 20060101ALI20180226BHEP

Ipc: A61K 47/64 20170101AFI20180226BHEP

Ipc: C12N 15/00 20060101ALI20180226BHEP

Ipc: A61K 38/08 20060101ALI20180226BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: OREGON STATE UNIVERSITY

Owner name: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20191203

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1235827

Country of ref document: HK